WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 571254
Description: HBX 19,818 is a selective and irreversible USP7 inhibitor. HBX 19,818 has an IC50 of 28 μM In vivo activity for this compound has not yet been described.
MedKoo Cat#: 571254
Name: HBX 19,818
Chemical Formula: C25H28ClN3O
Exact Mass: 421.1921
Molecular Weight: 421.97
Elemental Analysis: C, 71.16; H, 6.69; Cl, 8.40; N, 9.96; O, 3.79
Synonym: HBX 19,818; HBX-41,818; HBX41,818; HBX 41818; HBX-41818; HBX41818
IUPAC/Chemical Name: N-(3-(benzyl(methyl)amino)propyl)-9-chloro-5,6,7,8-tetrahydroacridine-2-carboxamide
InChi Key: ZCALMLVWZSQGGR-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H28ClN3O/c1-29(17-18-8-3-2-4-9-18)15-7-14-27-25(30)19-12-13-23-21(16-19)24(26)20-10-5-6-11-22(20)28-23/h2-4,8-9,12-13,16H,5-7,10-11,14-15,17H2,1H3,(H,27,30)
SMILES Code: O=C(C1=CC=C(N=C(CCCC2)C2=C3Cl)C3=C1)N([H])CCCN(C)CC4=CC=CC=C4
Ubiquitin specific protease 7 (USP7) supports cancer by positively affecting tumor growth and negatively affecting the patient’s immune response to tumors. USP7 inhibitors thus are an avenue of interest in potential cancer treatment. USP7 plays an important role in antagonizing p53 functions through multiple mechanisms. p53 is a critical tumor suppressor, and mutations in p53 are found in more than 50% of human cancers.
1: Wu J, Kumar S, Wang F, Wang H, Chen L, Arsenault P, Mattern M, Weinstock J. Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies. J Med Chem. 2017 Aug 18. doi: 10.1021/acs.jmedchem.7b00498. [Epub ahead of print] PubMed PMID: 28768102.